AAPL356.27+1.39 (+0.39%) ▲|ABBV295.03+0.58 (+0.20%) ▲|ABT108.52+1.27 (+1.18%) ▲|ACN250.49+0.54 (+0.22%) ▲|ADBE243.08+4.54 (+1.90%) ▲|AMAT370.50-10.45 (-2.74%) ▼|AMD534.06-51.24 (-8.75%) ▼|AMGN465.67-1.39 (-0.30%) ▼|AMT191.64+1.85 (+0.97%) ▲|AMZN266.66-0.78 (-0.29%) ▼|AVGO347.01-17.35 (-4.76%) ▼|AXP320.60+2.54 (+0.80%) ▲|BA171.50-0.05 (-0.03%) ▼|BAC51.02+0.51 (+1.01%) ▲|BKNG159.58-1.62 (-1.01%) ▼|BLK1,222.91+6.30 (+0.52%) ▲|BMY63.43+1.11 (+1.78%) ▲|BNY153.41+0.62 (+0.41%) ▲|BRK-B592.94+3.11 (+0.53%) ▲|C124.01-0.05 (-0.04%) ▼|CAT600.20-5.08 (-0.84%) ▼|CL99.67+1.77 (+1.81%) ▲|CMCSA25.16+0.36 (+1.45%) ▲|COF195.08+1.48 (+0.76%) ▲|COP142.28+2.22 (+1.59%) ▲|COST1,106.21+14.00 (+1.28%) ▲|CRM217.84+0.27 (+0.12%) ▲|CSCO95.64-6.37 (-6.24%) ▼|CVS89.35-0.44 (-0.49%) ▼|CVX219.89+3.54 (+1.64%) ▲|DE673.54-5.25 (-0.77%) ▼|DHR233.02+0.86 (+0.37%) ▲|DIS118.97+0.74 (+0.63%) ▲|DUK129.16+1.66 (+1.30%) ▲|EMR166.38+0.06 (+0.03%) ▲|FDX324.14+4.84 (+1.52%) ▲|GD363.46+0.39 (+0.11%) ▲|GE331.81+0.95 (+0.29%) ▲|GEV803.13-15.36 (-1.88%) ▼|GILD168.08+0.13 (+0.08%) ▲|GM86.00-0.25 (-0.29%) ▼|GOOG292.52-2.83 (-0.96%) ▼|GOOGL295.77-2.93 (-0.98%) ▼|GS916.56+2.96 (+0.32%) ▲|HD348.69+0.43 (+0.12%) ▲|HON222.46-0.29 (-0.13%) ▼|IBM247.13+2.46 (+1.01%) ▲|INTC59.66-1.54 (-2.52%) ▼|INTU341.70+1.53 (+0.45%) ▲|ISRG443.59+3.70 (+0.84%) ▲|JNJ285.75+2.23 (+0.79%) ▲|JPM346.19+3.37 (+0.98%) ▲|KO99.25+1.81 (+1.86%) ▲|LIN526.06+3.57 (+0.68%) ▲|LLY1,443.50+17.95 (+1.26%) ▲|LMT596.04-8.05 (-1.33%) ▼|LOW227.73+0.27 (+0.12%) ▲|LRCX225.92-7.86 (-3.36%) ▼|MA661.19+8.59 (+1.32%) ▲|MCD271.97-1.66 (-0.61%) ▼|MDLZ67.54+0.98 (+1.47%) ▲|MDT102.86+1.87 (+1.85%) ▲|META641.69+18.08 (+2.90%) ▲|MMM183.66-1.80 (-0.97%) ▼|MO78.64+0.72 (+0.92%) ▲|MRK147.76+0.81 (+0.55%) ▲|MS190.65+1.48 (+0.78%) ▲|MSFT523.88+0.88 (+0.17%) ▲|MU778.31-20.13 (-2.52%) ▼|NEE85.12-0.17 (-0.20%) ▼|NFLX62.15-0.54 (-0.86%) ▼|NKE37.99+0.23 (+0.61%) ▲|NOW102.25+1.59 (+1.58%) ▲|NVDA162.85-3.34 (-2.01%) ▼|ORCL125.35-1.76 (-1.38%) ▼|PEP145.44+3.18 (+2.24%) ▲|PFE28.89+0.06 (+0.21%) ▲|PG169.80+1.77 (+1.05%) ▲|PLTR167.99-3.59 (-2.09%) ▼|PM198.96+2.30 (+1.17%) ▲|QCOM172.47-4.67 (-2.64%) ▼|RTX198.58+0.22 (+0.11%) ▲|SBUX106.44-0.19 (-0.18%) ▼|SCHW92.98+1.58 (+1.73%) ▲|SO93.59+1.12 (+1.21%) ▲|SPG232.97-0.64 (-0.27%) ▼|T22.18+0.00 (+0.00%) ▲|TMO700.22+0.78 (+0.11%) ▲|TMUS169.95-1.08 (-0.63%) ▼|TSLA390.22-7.23 (-1.82%) ▼|TXN303.60-8.88 (-2.84%) ▼|UBER69.69+0.57 (+0.82%) ▲|UNH407.46+2.33 (+0.58%) ▲|UNP302.44-1.76 (-0.58%) ▼|UPS112.40+2.02 (+1.83%) ▲|USB60.99+0.52 (+0.86%) ▲|V425.76+5.45 (+1.30%) ▲|VZ46.36-0.19 (-0.41%) ▼|WFC86.05+0.29 (+0.34%) ▲|WMT128.09+1.90 (+1.51%) ▲|XOM170.59+0.81 (+0.48%) ▲|AAPL356.27+1.39 (+0.39%) ▲|ABBV295.03+0.58 (+0.20%) ▲|ABT108.52+1.27 (+1.18%) ▲|ACN250.49+0.54 (+0.22%) ▲|ADBE243.08+4.54 (+1.90%) ▲|AMAT370.50-10.45 (-2.74%) ▼|AMD534.06-51.24 (-8.75%) ▼|AMGN465.67-1.39 (-0.30%) ▼|AMT191.64+1.85 (+0.97%) ▲|AMZN266.66-0.78 (-0.29%) ▼|AVGO347.01-17.35 (-4.76%) ▼|AXP320.60+2.54 (+0.80%) ▲|BA171.50-0.05 (-0.03%) ▼|BAC51.02+0.51 (+1.01%) ▲|BKNG159.58-1.62 (-1.01%) ▼|BLK1,222.91+6.30 (+0.52%) ▲|BMY63.43+1.11 (+1.78%) ▲|BNY153.41+0.62 (+0.41%) ▲|BRK-B592.94+3.11 (+0.53%) ▲|C124.01-0.05 (-0.04%) ▼|CAT600.20-5.08 (-0.84%) ▼|CL99.67+1.77 (+1.81%) ▲|CMCSA25.16+0.36 (+1.45%) ▲|COF195.08+1.48 (+0.76%) ▲|COP142.28+2.22 (+1.59%) ▲|COST1,106.21+14.00 (+1.28%) ▲|CRM217.84+0.27 (+0.12%) ▲|CSCO95.64-6.37 (-6.24%) ▼|CVS89.35-0.44 (-0.49%) ▼|CVX219.89+3.54 (+1.64%) ▲|DE673.54-5.25 (-0.77%) ▼|DHR233.02+0.86 (+0.37%) ▲|DIS118.97+0.74 (+0.63%) ▲|DUK129.16+1.66 (+1.30%) ▲|EMR166.38+0.06 (+0.03%) ▲|FDX324.14+4.84 (+1.52%) ▲|GD363.46+0.39 (+0.11%) ▲|GE331.81+0.95 (+0.29%) ▲|GEV803.13-15.36 (-1.88%) ▼|GILD168.08+0.13 (+0.08%) ▲|GM86.00-0.25 (-0.29%) ▼|GOOG292.52-2.83 (-0.96%) ▼|GOOGL295.77-2.93 (-0.98%) ▼|GS916.56+2.96 (+0.32%) ▲|HD348.69+0.43 (+0.12%) ▲|HON222.46-0.29 (-0.13%) ▼|IBM247.13+2.46 (+1.01%) ▲|INTC59.66-1.54 (-2.52%) ▼|INTU341.70+1.53 (+0.45%) ▲|ISRG443.59+3.70 (+0.84%) ▲|JNJ285.75+2.23 (+0.79%) ▲|JPM346.19+3.37 (+0.98%) ▲|KO99.25+1.81 (+1.86%) ▲|LIN526.06+3.57 (+0.68%) ▲|LLY1,443.50+17.95 (+1.26%) ▲|LMT596.04-8.05 (-1.33%) ▼|LOW227.73+0.27 (+0.12%) ▲|LRCX225.92-7.86 (-3.36%) ▼|MA661.19+8.59 (+1.32%) ▲|MCD271.97-1.66 (-0.61%) ▼|MDLZ67.54+0.98 (+1.47%) ▲|MDT102.86+1.87 (+1.85%) ▲|META641.69+18.08 (+2.90%) ▲|MMM183.66-1.80 (-0.97%) ▼|MO78.64+0.72 (+0.92%) ▲|MRK147.76+0.81 (+0.55%) ▲|MS190.65+1.48 (+0.78%) ▲|MSFT523.88+0.88 (+0.17%) ▲|MU778.31-20.13 (-2.52%) ▼|NEE85.12-0.17 (-0.20%) ▼|NFLX62.15-0.54 (-0.86%) ▼|NKE37.99+0.23 (+0.61%) ▲|NOW102.25+1.59 (+1.58%) ▲|NVDA162.85-3.34 (-2.01%) ▼|ORCL125.35-1.76 (-1.38%) ▼|PEP145.44+3.18 (+2.24%) ▲|PFE28.89+0.06 (+0.21%) ▲|PG169.80+1.77 (+1.05%) ▲|PLTR167.99-3.59 (-2.09%) ▼|PM198.96+2.30 (+1.17%) ▲|QCOM172.47-4.67 (-2.64%) ▼|RTX198.58+0.22 (+0.11%) ▲|SBUX106.44-0.19 (-0.18%) ▼|SCHW92.98+1.58 (+1.73%) ▲|SO93.59+1.12 (+1.21%) ▲|SPG232.97-0.64 (-0.27%) ▼|T22.18+0.00 (+0.00%) ▲|TMO700.22+0.78 (+0.11%) ▲|TMUS169.95-1.08 (-0.63%) ▼|TSLA390.22-7.23 (-1.82%) ▼|TXN303.60-8.88 (-2.84%) ▼|UBER69.69+0.57 (+0.82%) ▲|UNH407.46+2.33 (+0.58%) ▲|UNP302.44-1.76 (-0.58%) ▼|UPS112.40+2.02 (+1.83%) ▲|USB60.99+0.52 (+0.86%) ▲|V425.76+5.45 (+1.30%) ▲|VZ46.36-0.19 (-0.41%) ▼|WFC86.05+0.29 (+0.34%) ▲|WMT128.09+1.90 (+1.51%) ▲|XOM170.59+0.81 (+0.48%) ▲|
3.9 C
New York
Saturday, November 14, 2026

Tag: news

Resurgent Realty Trust Issue Position Statement Regarding Generation Income Properties, Inc. (“GIPR”)

Cites Continued Failure to Perform Fiduciary Duty by GIPR Management and Board of Directors
Cites Continued Failure to Perform Fiduciary Duty by GIPR Management and Board of Directors

22q11.2 Deletion Syndrome Market Research Report 2025: Zynerba Pharmaceuticals is at the Forefront with Its Clinical-stage Therapy Zygel (ZYN002)

22q11.2 deletion syndrome, also known as DiGeorge syndrome, is a genetic disorder caused by a chromosome 22 deletion, presenting symptoms like heart defects, immune deficiencies, and developmental delays. Market growth is driven by advancements in diagnostic technologies like next-generation sequencing (NGS) and chromosomal microarray analysis (CMA), enabling early detection and tailored interventions. Despite the lack of a cure, targeted therapies, such as Zynerba Pharmaceuticals' Zygel, are emerging. Increased awareness, research funding, and strategic collaborations are enhancing patient care and shaping a promising future for the 22q11.2 deletion syndrome market.
22q11.2 deletion syndrome, also known as DiGeorge syndrome, is a genetic disorder caused by a chromosome 22 deletion, presenting symptoms like heart defects, immune deficiencies, and developmental delays. Market growth is driven by advancements in diagnostic technologies like next-generation sequencing (NGS) and chromosomal microarray analysis (CMA), enabling early detection and tailored interventions. Despite the lack of a cure, targeted therapies, such as Zynerba Pharmaceuticals' Zygel, are emerging. Increased awareness, research funding, and strategic collaborations are enhancing patient care and shaping a promising future for the 22q11.2 deletion syndrome market.

Dr. Anosh Ahmed Announces Major Expansion of COVID Testing Contracts Across U.S. and International Markets

Dr. Anosh Ahmed expands U.S. and international COVID testing contracts with focus on compliance, fraud prevention, and trusted public health services
Dr. Anosh Ahmed expands U.S. and international COVID testing contracts with focus on compliance, fraud prevention, and trusted public health services

OneView’s Composable Unified Commerce Capabilities Support Australia Post’s Digital Transformation

The new OneView point of sale performed exceptionally well in the first peak season, with record transaction volumes executed BOSTON, June 25, 2025 /PRNewswire/ --...

OneView’s Composable Unified Commerce Capabilities Support Australia Post’s Digital Transformation

The new OneView point of sale performed exceptionally well in the first peak season, with record transaction volumes executed BOSTON, June 25, 2025 /PRNewswire/ --...

OneView’s Composable Unified Commerce Capabilities Support Australia Post’s Digital Transformation

The new OneView point of sale performed exceptionally well in the first peak season, with record transaction volumes executed BOSTON, June 25, 2025 /PRNewswire/ --...

Lakeland Capital Welcomes 2025 Summer Interns

CHARLESTON, S.C., June 25, 2025 (GLOBE NEWSWIRE) -- Lakeland Capital, a Charleston-based private, multifamily investment company active in select East Coast markets, is pleased to welcome Margaret Cover and Michael Smyth to its 2025 summer intern class.

Edge AI Software | A $8.91B Market by 2030 | How Real-Time Intelligence at the Edge Is Powering the Next Tech Revolution

CHICAGO, June 25, 2025 /PRNewswire/ -- The Edge AI Software Market is projected to be valued at USD 1.95 billion in 2024 and reach USD 8.91 billion by 2030,...

Edge AI Software | A $8.91B Market by 2030 | How Real-Time Intelligence at the Edge Is Powering the Next Tech Revolution

CHICAGO, June 25, 2025 /PRNewswire/ -- The Edge AI Software Market is projected to be valued at USD 1.95 billion in 2024 and reach USD 8.91 billion by 2030,...

Family Fun Shrinks for Summer with Lil McDonald’s

On July 1, fans across the U.S. can bring a pocket-size piece of McDonald's home with one of 21 miniature toys CHICAGO, June 25,...

Pharmacists Expand Clinical Footprint Across U.S. Hospitals

ASHP Survey Reports Growth in Pharmacy Roles in Hospital and Ambulatory Care BETHESDA, Md., June 25, 2025 /PRNewswire/ -- Health-system pharmacists are playing a larger role...

Wondera Partners with SourceAudio to License Industry-Leading Ethical Music Dataset for AI Training

Ethical AI meets music creation as Wondera trains with rights-cleared songs, building trust with artists and the future of generative music. NEW YORK, June 25,...

Bank al Etihad and INVESTBANK Set Merger in Motion in Jordan’s Largest Banking Deal

AMMAN, Jordan, June 25, 2025 /PRNewswire/ -- In a defining moment for Jordan's financial sector, Bank al Etihad and INVESTBANK have received shareholder approval...

Crédit Agricole Brie Picardie : Informations au titre du pilier 3 au 31 mars 2025

Crédit Agricole Brie Picardie : Informations au titre du pilier 3 au 31 mars 2025

- A word from our sponsors -

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsNews